iuvo molecule

Leadership Team

Ben Burton

Ben Burton

President and CEO

Prior to co-founding iuvo BioScience and taking on the roles of President and CEO, Ben was Vice President of Quality for the Pharmaceutical, Solutions and External Manufacturing organizations of Valeant Pharmaceuticals. Prior to the acquisition of Bausch + Lomb by Valeant, Ben served as Global VP of Quality for the Pharmaceutical Business Unit, and was a member of the B+L Global Leadership Team.

Earlier in his career, he held the position of Director, Quality and Technical Services for Norwich Pharmaceuticals (a contract manufacturing and development organization), responsible for driving new business development and revenue and leading the technical services organization (project managers, engineers, formulators, method developers, etc.) in delivering customer projects, as well as heading up the site quality organization. Ben began his career with Procter & Gamble Pharmaceuticals as a Process Engineer, moving up to roles of increasing responsibility in Product Development, OTC Engineering (Cayey, PR) and Global Clinical Supplies.

Ben holds a BS from Carnegie Mellon University with a double major in Chemical Engineering and Biomedical Engineering, and a dual MS/MAT in Chemistry and Education from Binghamton University.

Mary Richardson, PhD, DABT

Mary Richardson, PhD, DABT

Chief Scientific Officer, Executive Vice President

As Chief Scientific Officer at iuvo and one of the company’s co-founders, Mary heads up the Research and Development team. Most recently Mary served as Executive Director of Preclinical Development at Bausch + Lomb, continuing in that role when Valeant Pharmaceuticals purchased the company. Previously, she had been Director of Nonclinical Safety.

Her extensive background includes in-depth research and development experience covering the full range of the preclinical product life cycle. This includes discovery, product development, and post-market support in areas including life cycle management, geo-expansion, and manufacturing. She brings exhaustive knowledge of global regulations and standards for registration of pharmaceutical and medical device products.

Her technical leadership and expertise in drug development of small molecules, peptides, and medical devices has resulted in regulatory approval and success of numerous NDAs, INDs, IMPDs, and 510(k) submissions. She’s an in-demand speaker with many published articles in scientific journals.

Mary earned her PhD from the University of Rochester School of Medicine and Dentistry and is a highly experienced board-certified toxicologist (Diplomate of American Board of Toxicology – DABT) with broad-based technical skills in pharmaceuticals, OTC, medical devices, drug metabolism, toxicology, pharmacokinetics, and pharmacology.

Donna Ventura

Donna Ventura

Director, Toxicology

Donna is responsible for overseeing microbiology, toxicology, and chemistry laboratory operations. She is also responsible for the regulatory, accreditation, and environmental requirements for the company, serves as a primary liaison for the veterinary care program, and participates in the institutional animal care and use committee. Donna provides consulting services including customer support and protocol development for biocompatibility and safety studies.

Before iuvo, Donna acquired over thirty years of medical device and pharmaceutical development and testing experience, in positions such as Manager of Toxicology for STS Duotek and Ethox International. She participates in the Sterilization Working Group for the Association of the Advancement of Medical Instrumentation (AAMI), and is the liaison for the Association for the Advancement and Accreditation of Laboratory Animal Care (AAALAC). Like Ben and Mary, Donna spent significant time at Bausch + Lomb, supporting the research and development program for lens materials and lens care formulations.

Donna graduated from the Rochester Institute of Technology with a BS in Biology.

Karen Skuse

Karen Skuse

Finance Manager

Karen Skuse has been with iuvo BioScience since its inception, continuing in the position she held at MOOG Medical Devices since 2007.

Karen is responsible for oversight of the Finance department, and has responsibilities including preparing financial statements, executing the monthly closing process and the year-end audit process, and acting as the liaison between iuvo management and the company’s outside financial advisors.  Karen also provides revenue updates to management and the operational staff. 

Karen is involved in dealing with customers, from setting up new customers, through order entry and invoicing.  Karen is also manages vendor qualification and assessment of critical suppliers, and also manages employee payroll.

Karen graduated from Nazareth College with a B.A. in Business Administration.

John Lanzafame

John Lanzafame

Director, Business Development

John focuses on business development for iuvo BioScience in the medical device industry. John brings over twenty-five years of experience in companies focused on B2B sales of services and technologies in the medical device sector, combining extensive experience in business development, sales, marketing and executive-level management with a strong technical background in product development and commercialization.

He has negotiated dozens of strategic partnership and technology licenses between diverse entities ranging from startups to Fortune 50 companies to leading government research laboratories and universities.  John has also led product development organizations for a diverse range of products, ranging from Class 3 to Class 1 medical devices and pharmaceutical formulations for novel oncology treatments. 

Prior to joining iuvo, John has served in a variety of leading positions in both public and private companies, including as CEO of Isoflux Incorporated, a private technology company serving the medical device and optics industries; President of MyoCardioCare, Inc., a private medical device company; CEO of Biophan Technologies, Inc., a public medical technology development company; and President of STS Biopolymers, Inc., a private OEM company that developed high performance polymer coatings for the medical device industry, including lubricious coatings for catheters and guidewires and drug eluting coatings for stents and central catheters.  He has also served on the boards of directors of several private and public companies.

John holds a bachelor’s degree in chemical engineering from the University of Dayton and a master’s degree in industrial engineering management from Rochester Institute of Technology.